Press Releases March 27, 2026 04:30 PM

TRG Latin America Acquisitions Corp. Announces Closing of Partial Exercise of IPO Over-Allotment Option

TRG Latin America Acquisitions Corp. announces partial exercise of IPO over-allotment option, raising an additional $6.32 million.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
TRGSU

TRG Latin America Acquisitions Corp. announced that its IPO underwriter exercised part of its over-allotment option, purchasing an additional 632,000 units at $10 each. This raises the total units sold to 20,632,000 and gross proceeds to over $206 million, strengthening the company's capital for future business combinations.

TRG Latin America Acquisitions Corp. Announces Closing of Partial Exercise of IPO Over-Allotment Option
TRGSU
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Underwriter partially exercised IPO over-allotment option, adding $6.32 million in gross proceeds.
  • Total IPO gross proceeds now exceed $206 million, enhancing the company's financial resources.
  • Units consist of Class A ordinary shares plus rights convertible upon an initial business combination, with upcoming Nasdaq listings under TRGS and TRGSR.

New York, NY, March 27, 2026 (GLOBE NEWSWIRE) --  TRG Latin America Acquisitions Corp. (the “Company”) (NASDAQ: TRGSU), announced today that the underwriter of its previously consummated initial public offering has partially exercised its option to purchase an additional 632,000 units at the public offering price of $10.00 per unit, resulting in additional gross proceeds of $6,320,000. The underwriter has a remaining option to purchase up to 2,368,000 additional units.

After giving effect to this partial exercise of the over-allotment option, the total number of units sold in the public offering increased to 20,632,000 units, resulting in total gross proceeds of $206,320,000 for the Company’s initial public offering.

Each unit consists of one Class A ordinary share and one right entitling the holder thereof to receive one-tenth of one Class A ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on Nasdaq under the symbols “TRGS” and “TRGSR,” respectively.

Santander acted as sole book-running manager for the offering.

The offering was made by means of a prospectus. Copies of the prospectus may be obtained from Santander US Capital Markets LLC, 437 Madison Avenue, New York, NY 10022, Attention: ECM Syndicate, by email at [email protected], or by telephone at 833-818-1602.
  
A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on February 25, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the anticipated use of the net proceeds thereof. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s offering filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. 

Investor Contact:

Investor Relations Team
[email protected]


Risks

  • Use of net proceeds is subject to uncertainties and may differ from current expectations, affecting investment outcome.
  • Forward-looking statements depend on many conditions beyond company control, including regulatory and market factors.
  • Regulatory restrictions exist regarding the offer, sale, or solicitation of securities until proper registration or qualification, limiting some investor access.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026